156 related articles for article (PubMed ID: 12820476)
1. Gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the urothelium: a pilot study.
Culine S; Rebillard X; Iborra F; Mottet N; Faix A; Ayuso D; Pinguet F
Anticancer Res; 2003; 23(2C):1903-6. PubMed ID: 12820476
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer.
Carles J; Esteban E; Climent M; Font A; Gonzalez-Larriba JL; Berrocal A; Garcia-Ribas I; Marfa X; Fabregat X; Albanell J; Bellmunt J;
Ann Oncol; 2007 Aug; 18(8):1359-62. PubMed ID: 17693649
[TBL] [Abstract][Full Text] [Related]
3. A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract.
Theodore C; Bidault F; Bouvet-Forteau N; Abdelatif M; Fizazi K; di Palma M; Wibault P; de Crevoisier R; Laplanche A
Ann Oncol; 2006 Jun; 17(6):990-4. PubMed ID: 16600984
[TBL] [Abstract][Full Text] [Related]
4. Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
Kitamura H; Takahashi A; Hotta H; Kato R; Kunishima Y; Takei F; Horita H; Masumori N;
Int J Urol; 2015 Oct; 22(10):911-4. PubMed ID: 26087891
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
Lee JL; Ahn JH; Park SH; Lim HY; Kwon JH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Invest New Drugs; 2012 Oct; 30(5):1984-90. PubMed ID: 22012004
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
Alva A; Daignault S; Smith DC; Hussain M
Invest New Drugs; 2014 Feb; 32(1):188-94. PubMed ID: 24318901
[TBL] [Abstract][Full Text] [Related]
7. Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features.
Shannon C; Crombie C; Brooks A; Lau H; Drummond M; Gurney H
Ann Oncol; 2001 Jul; 12(7):947-52. PubMed ID: 11521800
[TBL] [Abstract][Full Text] [Related]
8. [Gemcitabine and carboplatin chemotherapy in advanced transitional cell carcinoma in regard to patients with impaired renal function].
Helke C; May M; Hoschke B
Aktuelle Urol; 2006 Sep; 37(5):363-8. PubMed ID: 17004181
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French Genitourinary Tumor Group (GETUG V01).
Culine S; Fléchon A; Guillot A; Le Moulec S; Pouessel D; Rolland F; Ravaud A; Houédé N; Mignot L; Joly F; Oudard S; Gourgou S
Eur Urol; 2011 Dec; 60(6):1251-7. PubMed ID: 21924547
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine, paclitaxel, and cisplatin as combined adjuvant approach in transitional cell carcinoma of the urothelium.
Ecke TD; Gerullis H; Bartel P; Koch S; Ruttloff J
Minerva Urol Nefrol; 2009 Sep; 61(3):249-56. PubMed ID: 19773726
[TBL] [Abstract][Full Text] [Related]
11. Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbidities.
Mir O; Alexandre J; Ropert S; Amsellem-Ouazana D; Flam T; Beuzeboc P; Zerbib M; Debré B; Guillevin L; Goldwasser F
Anticancer Drugs; 2005 Oct; 16(9):1017-21. PubMed ID: 16162979
[TBL] [Abstract][Full Text] [Related]
12. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.
Bellmunt J; Guillem V; Paz-Ares L; González-Larriba JL; Carles J; Batiste-Alentorn E; Sáenz A; López-Brea M; Font A; Nogué M; Bastús R; Climent MA; de la Cruz JJ; Albanell J; Banús JM; Gallardo E; Diaz-Rubio E; Cortés-Funes H; Baselga J
J Clin Oncol; 2000 Sep; 18(18):3247-55. PubMed ID: 10986057
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: a phase II study of the SUOC group.
Kitamura H; Taguchi K; Kunishima Y; Yanase M; Takahashi A; Shigyo M; Tanaka T; Mutoh M; Fukuta F; Masumori N; Tsukamoto T
Cancer Sci; 2011 Jun; 102(6):1171-5. PubMed ID: 21323791
[TBL] [Abstract][Full Text] [Related]
14. The first Slovak experience with second-line vinflunine in advanced urothelial carcinomas.
Palacka P; Mego M; Obertova J; Chovanec M; Sycova-Mila Z; Mardiak J
Klin Onkol; 2014; 27(6):429-33. PubMed ID: 25493582
[TBL] [Abstract][Full Text] [Related]
15. FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder.
Di Lorenzo G; Autorino R; Giordano A; Giuliano M; D'Armiento M; Bianco AR; De Placido S
Jpn J Clin Oncol; 2004 Dec; 34(12):747-50. PubMed ID: 15640506
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group.
Moore MJ; Winquist EW; Murray N; Tannock IF; Huan S; Bennett K; Walsh W; Seymour L
J Clin Oncol; 1999 Sep; 17(9):2876-81. PubMed ID: 10561365
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma.
Pagliaro LC; Millikan RE; Tu SM; Williams D; Daliani D; Papandreou CN; Logothetis CJ
J Clin Oncol; 2002 Jul; 20(13):2965-70. PubMed ID: 12089226
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study.
Neri B; Vannini L; Giordano C; Grifoni R; Pantaleo P; Baldazzi V; Crisci A; Lapini A; Raugei A; Carini M
Anticancer Drugs; 2007 Nov; 18(10):1207-11. PubMed ID: 17893522
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.
Moore MJ; Tannock IF; Ernst DS; Huan S; Murray N
J Clin Oncol; 1997 Dec; 15(12):3441-5. PubMed ID: 9396395
[TBL] [Abstract][Full Text] [Related]
20. Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653).
Sadeghi S; Groshen SG; Tsao-Wei DD; Parikh R; Mortazavi A; Dorff TB; Kefauver C; Hoimes C; Doyle L; Quinn DI; Newman E; Lara PN
J Clin Oncol; 2019 Oct; 37(29):2682-2688. PubMed ID: 31390274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
